Nomura Holdings
ESPR

Nomura Holdings’s Esperion Therapeutics ESPR Stock Holding History

Nomura Holdings’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-210,200
Closed -$9.65M – 1184
2018
Q4 		$9.65M Buy
210,200
+39,800
+23% +$1.92M 0.04% 336
2018
Q3 		$7.72M Buy
170,400
+90,400
+113% +$4.15M 0.03% 411
2018
Q2 		$3.13M Buy
80,000
+61,200
+326% +$3.09M 0.01% 606
2018
Q1 		$1.36K Buy
+18,800
New +$1.38M ﹤0.01% 966

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nomura Holdings's ESPR Position: Q2 2025 in Review

Nomura Holdings sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 23,578 shares — an estimated $34K sold.

Nomura Holdings first reported a position in ESPR in Q1 2018 and held it in 25 quarters. The position peaked at $32.7M in Q4 2019. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Nomura Holdings reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nomura Holdings sold 23,578 Esperion Therapeutics shares in Q2 2025, an estimated $34K.
  • Nomura Holdings first reported a position in Esperion Therapeutics in Q1 2018 and held it in 25 quarters.
  • Nomura Holdings's Esperion Therapeutics position peaked at $32.7M in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Nomura Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.